Nasus Pharma (NSRX) news

Nasus Pharma announces enrollment and dosing of first patient in phase 1 study of NS003 intranasal formulation of ondansetron

Nasus Pharma: Enters ATM sales agreement with BTIG for up to $8.50M in ordinary shares - SEC filing

Nasus Pharma has entered into an at-the-market (ATM) sales agreement with BTIG, LLC, granting the company the ability to sell up to $8.50 million in ordinary shares, as disclosed in a recent SEC filing [1]. Under the terms of the agreement, BTIG will act as the sales agent for the offering,…

Nasus Pharma: To use proceeds for NS002 clinical development, pipeline studies, working capital

Nasus Pharma Ltd. (NYSE: NSRX) has outlined its financial strategy to advance its lead candidate, NS002, toward a pivotal clinical study and to support broader pipeline development. The company reported $4.3 million in cash, cash equivalents, and marketable securities as of December 31, 2025, a…

Nasus Pharma Ltd: Enters at-the-market sales agreement with BTIG to offer ordinary shares

Nasus Pharma Ltd (NASDAQ: NSUS) has entered into an at-the-market (ATM) sales agreement with BTIG, LLC, granting the investment bank the authority to sell the company’s ordinary shares on a continuous basis, subject to market conditions and [Nasus Pharma’s discretion][1]. Under the agreement, BTIG…

Nasus Pharma - Pivotal study planned for Q4 2026; topline data readout anticipated Q1 2027

Nasus Pharma (NYSE: NSRX) has outlined plans to initiate a pivotal clinical study for its NS002 intranasal epinephrine powder in the fourth quarter of 2026, with topline data expected in the first quarter of 2027. The study follows the completion of a Phase 2 trial, which demonstrated statistically…